The greatest challenge for those wanting real reform from the health technology assessment review is not policy or methods but managing the bureaucracy and the games it is already playing to secure the outcomes it wants.
An appointment that is just another sign of a process in serious trouble
December 14, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 27 February
February 27, 2026 - - Podcast -
EU backs Australian-led consortium with up to $250m to advance next-generation influenza vaccines
February 26, 2026 - - Latest News -
United front forms across Asia Pacific to change the future of Pulmonary Arterial Hypertension
February 26, 2026 - - Latest News -
There are, in effect, two Pharmaceutical Benefits Schemes operating in Australia today
February 26, 2026 - - Latest News -
Reading the room on reform might mean following the Budget message
February 25, 2026 - - Latest News -
Weight-loss medicines approved in New Zealand, and recommended for funding, but pathway remains unclear
February 25, 2026 - -
Neurizon advances ALS drug program as funding, trials and global partnerships gain momentum
February 25, 2026 - - Australian Biotech

